Vision Impairments



Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia


Condition:   Amyotrophic Lateral Sclerosis
Intervention:  
Sponsor:   Jose Luis Urcelay Segura
Recruiting


Randomized Controlled Trial Evaluating an Incentive-based Community Eye-care Programme


Condition:   Visual Impairment
Intervention:   Other: Incentive Care
Sponsor:   Singapore National Eye Centre
Active, not recruiting


Cell Phone Application for Vision Assessment


Condition:   Visual Impairment
Interventions:   Other: Peek Acuity;   Other: Standard Visual Screening
Sponsor:   Duke University
Recruiting


Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2


Condition:   Ocular Conditions Resulting in Visual Impairment
Intervention:   Device: Colored near reading glasses
Sponsor:   Nova Southeastern University
Recruiting


Feasibility and Efficacy of Assisstive Tactile and Auditory Communicating Devices


Condition:   Visual Impairment
Intervention:   Behavioral: standard object battery and training sequence
Sponsor:   New York University School of Medicine
Not yet recruiting


Ocular and Vision Problems in Patients After Fontan Operation


Condition:   Congenital Heart Disease
Intervention:  
Sponsor:   Stanford University
Recruiting


Peripheral Vision Training Study


Conditions:   Visual Impairment;   Cognitive Change
Intervention:   Other: computerized training
Sponsor:   University of Alabama at Birmingham
Recruiting


MRI Screening for Auditory Pathway Malformations in Visually Impaired Children


Condition:   Visual Impairment
Intervention:  
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting


24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.


Condition:   Visual Impairment Due to Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Withdrawn


Evaluation of Tests Performance on a New Digital Orthoptic Platform


Conditions:   Binocular Vision Disorder;   Visual Impairment
Intervention:  
Sponsor:   University Hospital, Brest
Completed


The Baltimore Reading and Eye Disease Study


Conditions:   Refractive Error;   Visual Impairment;   Convergence Insufficiency;   Reading Disabilities
Interventions:   Behavioral: Eyeglass wearing;   Behavioral: Orthoptic exercises;   Other: Specialist referral
Sponsor:   Johns Hopkins University
Active, not recruiting


Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema


Condition:   Visual Impairment Due to Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Withdrawn


A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients


Conditions:   Diabetic Macular Edema;   Visual Impairment
Interventions:   Drug: ranibizumab;   Procedure: laser
Sponsor:   Novartis Pharmaceuticals
Completed


Measuring of Neuro-visual Functionality With Ocusweep


Condition:   Visual Impairment
Intervention:   Device: Ocusweep
Sponsor:   Ocuspecto Oy
Recruiting


Observation of Treatment Patterns With Lucentis in Approved Indications


Condition:   Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Intervention:  
Sponsor:   Novartis Pharmaceuticals
Completed


A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.


Condition:   Choroidal Neovascularization Secondary to Pathologic Myopia
Intervention:   Drug: Ranibizumab
Sponsor:   Novartis Pharmaceuticals
Completed


Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD


Condition:   Visual Impairment Due to Neovascular AMD
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Completed


Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia


Condition:   Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Interventions:   Drug: Ranibizumab 0.5mg;   Drug: Rranibizumab 0.5 mg;   Drug: Verteporfin PDT
Sponsor:   Novartis Pharmaceuticals
Completed


Nitisinone for Type 1B Oculocutaneous Albinism


Conditions:   Albinism;   Vision Loss
Intervention:   Drug: Nitisinone (NTBC)
Sponsors:   National Eye Institute (NEI);   National Human Genome Research Institute (NHGRI)
Active, not recruiting


Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion


Conditions:   Macular Edema;   Central Retinal Vein Occlusion
Intervention:   Drug: Ranibizumab 0.5 mg/0.05 ml
Sponsor:   Novartis Pharmaceuticals
Completed


Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration


Condition:   Age Related Macular Degeneration
Interventions:   Device: Telescope prosthesis;   Device: WA-NG Telescope Prothesis
Sponsor:   VisionCare, Inc.
Withdrawn


A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema


Conditions:   Visual Impairment;   Macular Edema
Intervention:   Drug: Ranibizumab
Sponsor:   Novartis Pharmaceuticals
Completed


Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema


Conditions:   Diabetic Macular Edema;   Visual Impairment
Interventions:   Drug: RFB002;   Procedure: Laser photocoagulation
Sponsor:   Novartis Pharmaceuticals
Completed


Health Intervention for Adolescents With Intellectual Disability


Conditions:   Vision Impairment;   Hearing Impairment;   Obesity
Intervention:   Behavioral: Health Intervention Package
Sponsors:   The University of Queensland;   National Health and Medical Research Council, Australia
Completed


Providing Access to the Visual Environment


Condition:   Vision Impairment
Intervention:  
Sponsors:   Vanderbilt University;   Tennessee Department of Education
Recruiting

Refine Your Search Advanced Search